EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma



RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma



Clinical Cancer Research 20(11): 2933-2946



Cetuximab, an antibody directed against the EGF receptor, is an effective clinical therapy for patients with head and neck squamous cell cancer (HNSCC). Despite great clinical promise, intrinsic or acquired cetuximab resistance hinders successful treatment outcomes but little is known about the underlying mechanism. To study the role of oncogenic HRAS in cetuximab resistance in HNSCC, the frequency of oncogenic HRAS mutations was determined in a cohort of 180 genomic DNAs from head and neck cancer specimens. We also used a combination of cetuximab-resistant cell lines and a transgenic mouse model of RAS-driven oral cancer to identify an oncogenic RAS-specific gene expression signature that promotes cetuximab resistance. Here, we show that activation of RAS signaling leads to persistent extracellular signal-regulated kinase 1/2 signaling and consequently to cetuximab resistance. HRAS depletion in cells containing oncogenic HRAS or PIK3CA restored cetuximab sensitivity. In our study, the gene expression signature of c-MYC, BCL-2, BCL-XL, and cyclin D1 upon activation of MAPK signaling was not altered by cetuximab treatment, suggesting that this signature may have a pivotal role in cetuximab resistance of RAS-activated HNSCC. Finally, a subset of patients with head and neck cancer with oncogenic HRAS mutations was found to exhibit de novo resistance to cetuximab-based therapy. Collectively, these findings identify a distinct cetuximab resistance mechanism. Oncogenic HRAS in HNSCC promotes activation of ERK signaling, which in turn mediates cetuximab resistance through a specific gene expression signature. Clin Cancer Res; 20(11); 2933-46. ©2014 AACR.

(PDF emailed within 0-6 h: $19.90)

Accession: 055333431

Download citation: RISBibTeXText

PMID: 24696319

DOI: 10.1158/1078-0432.CCR-13-2721



Related references

PI3K/PTEN/AKT/mTOR polymorphisms: association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximab-docetaxel. Head & Neck 37(4): 471-478, 2016

The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma. Medical Oncology 36(1): 8-8, 2018

MiR-223-3p inhibits angiogenesis and promotes resistance to cetuximab in head and neck squamous cell carcinoma. Oncotarget 8(34): 57174-57186, 2017

Nicotine promotes lymph node metastasis and cetuximab resistance in head and neck squamous cell carcinoma. International Journal of Oncology: -, 2018

Recurrence Patterns for Head and Neck Squamous Cell Carcinoma Treated with Cetuximab versus Non-cetuximab Therapy. Otolaryngology - Head and Neck Surgery 149(2 Suppl): P75-P76, 2013

Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. Plos One 5(9): E12702-E12702, 2011

Feasibility of 6-month maintenance cetuximab after adjuvant concurrent chemoradiation plus cetuximab in squamous cell carcinoma of the head and neck. Strahlentherapie und Onkologie 189(8): 625-631, 2013

Feasibility of 6 Months Maintenance Cetuximab After Adjuvant Concurrent Chemoradiation Plus Cetuximab in Squamous Cell Carcinoma of the Head and Neck. International Journal of Radiation Oncology*biology*physics 87(2): S462-S463, 2013

Cancer-associated fibroblasts induce matrix metalloproteinase-mediated cetuximab resistance in head and neck squamous cell carcinoma cells. Molecular Cancer Research 10(9): 1158-1168, 2014

Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma. Cancer Biology & Therapy 16(8): 1252-1258, 2016

The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines. Bmc Research Notes 8(): 203-203, 2016

Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines. Molecular Oncology 12(6): 830-854, 2018

Feasibility of Induction Docetaxel, Cisplatin, 5-Fluorouracil, Cetuximab (TPF-C) Followed by Concurrent Cetuximab Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology 3(): 5-5, 2013

Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma. Oncotarget 7(28): 42988-42995, 2016

Gene expression signatures modulated by epidermal growth factor receptor activation and their relationship to cetuximab resistance in head and neck squamous cell carcinoma. Bmc Genomics 13: 160-160, 2013